Clinical efficiency and dermoprotection of 2-ethyl-6-methyl-3-hydroxypyridine succinate drug in case of psoriasis: from the antioxidation point of view


  • V. A. Visir Zaporizhzhia State Medical University,
  • G. I. Makurina Zaporizhzhia State Medical University,



Antioxidants, PASI Index, Life Quality, 2-ethyl-6-methyl-3-hydroxypyridine Succinate, Clinical Study


Objective. To study the clinical significance of oxidative processes modulation within frames of 2-ethyl-6-methyl-3-hydroxypyridine succinate dermatropic efficiency assessment in patients with psoriasis affected by arterial hypertension.

Materials and methods. The results of this study are based on data of comprehensive examination and supervision of 30 patients suffering from psoriasis with different clinical forms such as normal levels of blood pressure (the control group) or in combination with hypertension (the study group).

Results. The comparative description of the antioxidative therapy efficiency was performed by the end of treatment. The findings showed significantly positive antioxidant-dependent mechanisms of 2-ethyl-6-methyl-3-hydroxypyridine succinate clinical efficiency in patients with psoriasis affected by arterial hypertension.

In case of patients with combined psoriasis and essential hypertension course 2-ethyl-6-methyl-3-hydroxypyridine succinate therapy caused reliable decrease of free-radical oxidation intensification in particular nitrosative (reliable decrease of nitrotyrosine) and oxidative (negative dynamics of endothelin-1 and positive dynamics as to glutathione metabolism) stresses. That, in its turn, decreased the evidence of apoptotic and inflammatory processes (caspase-8 and TNF-α regress) both directly and indirectly by means of mediating anti-inflammatory effect on endothelium cells and macrophages of anticoagulant proteinase through endothelial protein C receptor (EPCR) with production of components and structures of extracellular matrix and disturbance of microcirculation. Thus, it determines the key pathogenetic aspects of psoriasis. The decrease of VEGF expression indicators level (vascular endothelial growth factor) and serotonin, associated with this combined therapy, had stipulated statistically significant positive clinical and subjective effect in form of regress of dermatological changes (PASI index), decrease of itch (optimization of serotonin biosynthesis and reduction of methionine conversion (with homocysteine formation)) and improvement of life quality.

Conclusions. Taking into account potential influence of 2-ethyl-6-methyl-3-hydroxypyridine succinate on these pathophysiological predictors and pathogenesis, which are to some extent involved in formation and progression of psoriatic disease, use of 2-ethyl-6-methyl-3-hydroxypyridine succinate is sufficiently effective in conditions of psoriasis therapy optimization.


Cardiovascular psoriasis comorbidities, treatment with atorvastatin. J. of the American Academy of Dermatology, 70(1), 165–175.

Yeung, H., Takeshita, J, Mehta, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., et al. (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol, 149(10), 1173–1179. doi: 10.1001/jamadermatol.2013.5015.

Sunitha, S., Rajappa, M., Thappa, D. M., Chandrashekar, L., Munisamy, M., & Revathy, G. (2016) Is the Ratio of Antibodies Against Oxidized LDL to Oxidized LDL an Indicator of Cardiovascular Risk in Psoriasis? OmanMed J., 31(5), 390–393. doi: 10.5001/omj.2016.78.

Peluso, I., Cavaliere, A., & Palmery, M. (2016) Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis. J BiomedSci, 23(1), 52. doi: 10.1186/s12929-016-0268-x.

Gu, X., Nylander, E., Coates, P. J., & Nylander, K. (2015) Oxidation reductionis a key process for successful treatment of psoriasis by narrow-band UVB phototherapy. ActaDermVenereol, №95(2), 140–146. doi: 10.2340/00015555-1905.

Karbach, S., Croxford, A. L., Oelze, M., Schüler, R., Minwegen, D., Wegner, J., et al. (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler ThrombVascBiol, 34(12), 2658–2668. doi:10.1161/ATVBAHA.114.304108.

Candel, S. de Oliveira, S., López-Muñoz, A., García-Moreno, D., Espín-Palazón, R., Tyrkalska, S. D., et al. (2014) Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation. PLoSBiol, 12(5), e1001855. doi: 10.1371/journal.pbio.1001855.

Borska, L., Andrys, C., Krejsek, J., Palicka, V., Chmelarova, M., Hamakova, K. et al. (2014) Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation. OxidMedCellLongev, 2014, 302528.

Prussick, R., Prussick, L., & Gutman, J. (2013) Psoriasis Improvement in Patients Using Glutathione-enhancing, Nondenatured Whey Protein Isolate: A Pilot Study. J Clin Aesthet Dermatol, 6(10), 23–26.

Kothiwala, S. K., Khanna, N., Tandon, N., Naik, N., Sharma, V. K., Sharma, S., & Sreenivas, V. (2016) Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: A hospital-basedcross-sectional study. Indian J Dermatol Venereol Leprol, 82(5), 510–518. doi: 10.4103/0378-6323.183638.

Yeung, H., Takeshita, J., Mehtaetal, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., et al. (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol, 149(10), 1173–9. doi: 10.1001/jamadermatol.2013.5015.

Menter, A. (2016) Psoriasis and psoriatic arthritis overview. Am J Manag Care, 22(8), 216–224.

Cea-Calvo, L., Vanaclocha, F., Belinchónetal, I., Rincón, Ó., Juliá, B., Puig, L. (2016) Under diagnosis of Cardiovascular Risk Factors in Out patients with Psoriasis Followedat Hospital Dermatology Offices: The PSO-RISK Study. Acta Derm Venereol, 2016. doi: 10.2340/00015555-2434.

Ganzetti, G., Campanati, A., Molinelli, E., & Offidani, A. et al (2016) Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol, 8(2), 120–131. doi: 10.4330/wjc.v8.i2.120.

Egeberg, A., Khalid, U., Gislason, G. H., Mallbris, L., Skov, L., Hansen, P. R. (2016) Impact of Depression on Risk of Myocardial Infarction, Stroke and Cardiovascular Deathin Patients with Psoriasis: A Danish Nationwide Study. Acta Derm Venereol., 96(2), 218–221. doi: 10.2340/00015555-2218.

Machado-Pinto, J., Diniz Mdos, S., & Bavoso, N. C. (2016) Machado-Pinto J. Psoriasis: new comorbidities. An Bras Dermatol, 91(1), 8–14. doi: 10.1590/abd1806-4841.20164169.

De Vecchis, R., Baldi C., & Palmisani, L. (2016) Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeuticin sights coming from a meta-analysis of the literature data. Anatol J Cardiol., 16(1), 2–9. doi: 10.5152/akd.2015.6136.

Reich, K., Mrowietz, U., Radtke, M. A., Thaci, D., Rustenbach, S. J., Spehr, C., & Augustin, M. (2015) Drug safety of systemic treatments for psoriasis: results fromThe German Psoriasis Registry Pso Best. Arch Dermatol Res, 307(10), 875–83. doi: 10.1007/s00403-015-1593-8.

Tarkin, J. M., & Rudd, J. H. (2015) Psoriasis: More Than Just Skin Deep. Arterioscler Thromb Vasc Biol, 35(12), 2487–2488. doi: 10.1161/ATVBAHA.115.306560.


How to Cite

Visir VA, Makurina GI. Clinical efficiency and dermoprotection of 2-ethyl-6-methyl-3-hydroxypyridine succinate drug in case of psoriasis: from the antioxidation point of view. Zaporozhye medical journal [Internet]. 2016Nov.10 [cited 2024Feb.27];18(5). Available from:



Original research